Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13088099 | 0.94 | CHRNB2 (0.56) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3044684 | 0.83 | CHRNB2 (0.70) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL29187194 | 0.83 | GRM5 (0.54) | CYP2C9CYP2C19CYP3A4CYP1A2FFAR1 | |
| SCHEMBL5032508 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL7874407 | 0.81 | CYP2A6 (0.54) | CYP2A6CYP2D6CYP1A2 | |
| SCHEMBL22398085 | 0.79 | MAPK1 (0.54) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL1841748 | 0.79 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3673693 | 0.79 | CHRNB2 (0.69) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL28585298 | 0.78 | FFAR1 (0.51) | CYP2C9CYP2C19CYP3A4CYP1A2FFAR1 | |
| SCHEMBL3064618 | 0.78 | CHRNB2 (0.67) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117822002-A | Preparation method of cis-olefin compound | 深圳市环保科技集团股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | claimed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | claimed |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | claimed |
| EP-2173716-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | claimed |
| CN-117822002-A | Preparation method of cis-olefin compound | 深圳市环保科技集团股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | disclosed |
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2173716-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | DDT, TYR, DDC | CHRNB2 3920/4885CHRNA4 4074/4885CYP2A6 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.